Table 7 Ability of automated laboratory immunometric hCG tests to detect hCG variants in 30 serum samples from gestational trophoblastic disease and cancer patients.
From: New discoveries on the biology and detection of human chorionic gonadotropin
Diagnosis | Abbott AxSym hCGβ mIU/ml (% median) | Baxter Stratus hCG mIU/ml (% median) | Siemens ACS180 hCG mIU/ml (% median) | Beckman Access hCGβ mIU/ml (% median) | Siemens Immulite hCG mIU/ml (% median) |
|---|---|---|---|---|---|
Partial mole | 5 (112%) | 2 (53%) | 3 (72%) | 6 (127%) | 4 (88%) |
Choriocarcinoma | 7 (110%) | 3 (49%) | 5 (71%) | 9 (133%) | 6 (90%) |
Partial mole | 10 (107%) | 7 (73%) | 7 (70%) | 10 (108%) | 9 (93%) |
Complete mole | 16 (117%) | 12 (89%) | 14 (104%) | 15 (115%) | 13 (96%) |
Complete mole | 18 (132%) | 6 (42%) | 14 (104%) | 18 (131%) | 11 (84%) |
Complete mole | 16 (119%) | 7 (53%) | 11 (81%) | 16 (119%) | 11 (80%) |
Partial mole | 26 (110%) | 15 (62%) | 22 (95%) | 25 (105%) | 19 (81%) |
Complete mole | 40 (133%) | 15 (51%) | 30 (100%) | 36 (119%) | 29 (96%) |
Ovarian dysgerminoma | 85 (138%) | 34 (55%) | 63 (102%) | 72 (118%) | 47 (76%) |
Complete mole | 91 (116%) | 56 (71%) | 88 (112%) | 90 (114%) | 69 (88%) |
Testicular germ cell | 102 (124%) | 60 (73%) | 88 (107%) | 92 (112%) | 78 (95%) |
Partial mole | 88 (104%) | 59 (70%) | 81 (96%) | 91 (108%) | 81 (96%) |
Choriocarcinoma | 126 (126%) | 78 (78%) | 102 (102%) | 128 (128%) | 101 (101%) |
Partial mole | 153 (143%) | 69 (64%) | 103 (97%) | 121 (114%) | 110 (103%) |
Serous Ovarian Cancer | 70 (64%) | 1 (0.9%) | 65 (59%) | 67 (61%) | 115 (105%) |
Complete mole | 198 (130%) | 106 (70%) | 159 (104%) | 176 (116%) | 146 (96%) |
Partial mole | 245 (124%) | 138 (70%) | 188 (95%) | 214 (109%) | 206 (105%) |
Ovarian dysgerminoma | 221 (99%) | 64 (29%) | 226 (101%) | 242 (108%) | 184 (82%) |
Partial mole | 291 (127%) | 173 (75%) | 260 (113%) | 256 (111%) | 224 (97%) |
Partial mole | 48 (20%) | 9 (3.8%) | 31 (13%) | 15 (6.3%) | 235 (99%) |
Complete mole | 607 (108%) | 453 (81%) | 603 (108%) | 614 (110%) | 560 (100%) |
Partial mole | 668 (115%) | 475 (82%) | 725 (124%) | 782 (134%) | 555 (95%) |
Choriocarcinoma | 603 (93%) | 687 (107%) | 955 (148%) | 842 (131%) | 550 (85%) |
Complete mole | 717 (94%) | 759 (99%) | 999 (131%) | 924 (121%) | 769 (101%) |
Complete mole | 704 (91%) | 666 (86%) | 943 (122%) | 925 (97%) | 751 (119%) |
Complete mole | 1,109 (131%) | 655 (77%) | 904 (107%) | 972 (115%) | 827 (98%) |
Partial mole | 1,027 (112%) | 891 (98%) | 1,230 (135%) | 1,094 (120%) | 930 (102%) |
Complete mole | 9576 (69%) | 7995 (58%) | 6378 (46%) | 7437 (54%) | 16320 (118%) |
Complete mole | 21515 (42%) | 16305 (32%) | 17070 (33%) | 19005 (37%) | 52350 (102%) |
Choriocarcinoma | 13640 (102%) | 12145 (91%) | 12970 (97%) | 13310 (100%) | 14720 (111%) |
Varies by > 25% median | 11 of 30 results | 21 of 30 results | 10 of 30 results | 10 of 30 results | 0 results |